Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting
25 avr. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster...
Vor Bio Announces Retirement of Chief Medical Officer
14 avr. 2022 16h15 HE
|
Vor Biopharma
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer...
Vor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
14 mars 2022 16h30 HE
|
Vor Biopharma
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022New program VCAR33ALLO using healthy donor-derived T cells IND submission expected in 1H 2023Cash runway extended...
Vor to Participate in Three Upcoming Investor Conferences
28 févr. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
11 févr. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor to Participate in Two Upcoming Investor Conferences
04 janv. 2022 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will...
Vor to Participate in the JMP Securities Hematology and Oncology Summit
29 nov. 2021 08h00 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
19 nov. 2021 16h01 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief...
Vor Reports Third Quarter 2021 Financial Results and Provides Company Update
10 nov. 2021 16h10 HE
|
Vor Biopharma
VOR33 on track with initial clinical data expected in the first half of 2022Announced pipeline expansion with first multi-targeted Treatment System simultaneously targeting CD33 and CLL-1 for AML ...
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
09 nov. 2021 08h30 HE
|
Vor Biopharma
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of new data from its novel...